Similar articles

• Targeting CSF1R in Chronic GVHD - Lessons in Translation.

  Sarantopoulos S. Sarantopoulos S. N Engl J Med. 2024 Sep 19;391(11):1053-1055. doi: 10.1056/NEJMe2407731. N Engl J Med. 2024. PMID: 39292932 No abstract available.
• Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.

  Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Wolff D, et al. N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. N Engl J Med. 2024. PMID: 39292927 Clinical Trial.
• Humanized anti-CD25 monoclonal antibody treatment of steroid-refractory acute graft-versus-host disease: a Chinese single-center experience in a group of 64 patients.

  Tao T, Ma X, Yang J, Zou JY, Ji SM, Tan YS, Gong W, Du F, Xu J, Ye CM, Tang XW, Wu DP, Xue SL. Tao T, et al. Blood Cancer J. 2015 Apr 17;5(4):e308. doi: 10.1038/bcj.2015.33. Blood Cancer J. 2015. PMID: 25885428 Free PMC article. No abstract available.
• Clinical utility of rituximab in chronic graft-versus-host disease.

  Bates JS, Engemann AM, Hammond JM. Bates JS, et al. Ann Pharmacother. 2009 Feb;43(2):316-21. doi: 10.1345/aph.1L386. Epub 2009 Feb 3. Ann Pharmacother. 2009. PMID: 19193571 Review.
• Novel strategies for the treatment and diagnosis of graft-versus-host-disease.

  Ferrara JL. Ferrara JL. Best Pract Res Clin Haematol. 2007 Mar;20(1):91-7. doi: 10.1016/j.beha.2006.11.004. Best Pract Res Clin Haematol. 2007. PMID: 17336259 Review.